Published in Infect Immun on June 01, 2005
Advances in swine biomedical model genomics. Int J Biol Sci (2007) 2.40
Bordetella pertussis pathogenesis: current and future challenges. Nat Rev Microbiol (2014) 1.40
Maternal immunity provides protection against pertussis in newborn piglets. Infect Immun (2006) 0.98
The host defense peptide beta-defensin 1 confers protection against Bordetella pertussis in newborn piglets. Infect Immun (2006) 0.89
Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children. CMAJ (2006) 0.87
Immunoproteomic analysis of human serological antibody responses to vaccination with whole-cell pertussis vaccine (WCV). PLoS One (2010) 0.81
Low dose antigen exposure for a finite period in newborn rats prevents induction of mucosal tolerance. PLoS One (2012) 0.78
Protective Role of Passively Transferred Maternal Cytokines against Bordetella pertussis Infection in Newborn Piglets. Infect Immun (2017) 0.77
PBMC transcriptomic responses to primary and secondary vaccination differ due to divergent lean growth and antibody titers in a pig model. Physiol Genomics (2015) 0.75
Prior exposure to Bordetella species as an exclusion criterion in the baboon model of pertussis. J Vet Med Sci (2016) 0.75
CD71(+) erythroid suppressor cells impair adaptive immunity against Bordetella pertussis. Sci Rep (2017) 0.75
Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet (2003) 9.13
Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin. Infect Immun (1983) 5.03
Pertussis of adults and infants. Lancet Infect Dis (2002) 2.95
Human infections associated with Bordetella bronchiseptica. Clin Microbiol Rev (1991) 2.91
Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J (2004) 2.70
Bordetella species are distinguished by patterns of substantial gene loss and host adaptation. J Bacteriol (2004) 2.52
Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis (1990) 2.41
Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis (1990) 2.18
Vaccination strategies for mucosal immune responses. Clin Microbiol Rev (2001) 1.98
Trends in pertussis among infants in the United States, 1980-1999. JAMA (2003) 1.94
Immunity to Bordetella pertussis. Microbes Infect (2001) 1.86
Pertussis deaths: report of 23 cases in the United States, 1992 and 1993. Pediatrics (1996) 1.79
Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine (2003) 1.76
Immunologic response to early and routine DTP immunization in infants. Pediatrics (1984) 1.71
Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med (1990) 1.67
Antimicrobial activity of innate immune molecules against Streptococcus pneumoniae, Moraxella catarrhalis and nontypeable Haemophilus influenzae. BMC Infect Dis (2004) 1.63
A marked decrease in L-selectin expression by leucocytes in infants with Bordetella pertussis infection: leucocytosis explained? Respirology (2003) 1.59
Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production. J Exp Med (2000) 1.55
Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins. Infect Immun (1994) 1.50
Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis (2004) 1.48
Pertussis: The histological Lesion in the Respiratory Tract. J Med Res (1912) 1.45
Pertussis--United States, January 1992-June 1995. MMWR Morb Mortal Wkly Rep (1995) 1.34
The science and fiction of the "resurgence" of pertussis. Pediatrics (2003) 1.34
Transplacental and transcolostral immunity to pertussis in a mouse model using acellular pertussis vaccine. J Infect Dis (1983) 1.06
Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics (2003) 1.04
Pertussis: a worldwide problem. Dev Biol Stand (1997) 1.03
The structure of the nonreducing terminal groups in the O-specific polysaccharides from two strains of Bordetella bronchiseptica. Eur J Biochem (2000) 1.02
Xenogeneic transplantation of porcine islets: an overview. Transplantation (2003) 1.00
Signalling and cellular specificity of airway nitric oxide production in pertussis. Cell Microbiol (1999) 0.99
Autotoxicity of nitric oxide in airway disease. Am J Respir Crit Care Med (1996) 0.99
Development of a rat model for respiratory infection with Bordetella pertussis. Infect Immun (1989) 0.96
Ethical issues for vaccines and immunization. Nat Rev Immunol (2002) 0.94
The pig as a model of developmental immunology. Hum Exp Toxicol (2002) 0.94
Pertussis vaccines. Wkly Epidemiol Rec (1999) 0.92
Antibacterial peptides in bronchoalveolar lavage fluid. Am J Respir Cell Mol Biol (1998) 0.90
Use of Bordetella bronchiseptica and Bordetella pertussis as live vaccines and vectors for heterologous antigens. FEMS Immunol Med Microbiol (2003) 0.90
Maternal immunization. Clin Infect Dis (1999) 0.89
Bordetella pertussis infection of primary human monocytes alters HLA-DR expression. Infect Immun (2004) 0.87
Antibodies to Bordetella pertussis in human colostrum and their protective activity against aerosol infection of mice. Infect Immun (1985) 0.87
Are pertussis fatalities in infants on the rise? What can be done to prevent them? J Pediatr (2003) 0.86
Pertussis: an important target for maternal immunization. Vaccine (2003) 0.84
Maternal immunization. Obstet Gynecol Clin North Am (2003) 0.84
AN ATTEMPT TO INCREASE RESISTANCE TO PERTUSSIS IN NEWBORN INFANTS BY IMMUNIZING THEIR MOTHERS DURING PREGNANCY. J Clin Invest (1938) 0.83
Role of systemic and mucosal immune responses in reciprocal protection against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection. Infect Immun (2003) 0.81
Mucosal immunity: overcoming the barrier for induction of proximal responses. Immunol Res (2004) 0.79
[Pertussis in young infants]. Ned Tijdschr Geneeskd (1998) 0.79
Differences in coughing and other responses to intrabronchial infection with Bordetella pertussis among strains of rats. Infect Immun (1997) 0.77
Genetic diversity and relationships in populations of Bordetella spp. J Bacteriol (1986) 4.48
Use of pulsed-field gel electrophoresis for epidemiological study of Bordetella pertussis in a whooping cough outbreak. J Clin Microbiol (1994) 4.13
The use of fluorescein isothiocyanate in the determination of the bacterial biomass of grassland soil. Can J Microbiol (1970) 3.62
Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet (1993) 3.54
Invasion of HeLa 229 cells by virulent Bordetella pertussis. Infect Immun (1989) 3.27
Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis (2001) 3.11
Rotavirus isolation and cultivation in the presence of trypsin. J Clin Microbiol (1977) 2.99
Universal primers for fluorescent labelling of PCR fragments--an efficient and cost-effective approach to genotyping by fluorescence. Mol Ecol Resour (2012) 2.63
Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA (1998) 2.50
Isolation and characterization of isogenic pairs of domed hemolytic and flat nonhemolytic colony types of Bordetella pertussis. Infect Immun (1982) 2.47
Two physically and serologically distinct lipopolysaccharide profiles in strains of Bordetella pertussis and their phenotype variants. Infect Immun (1984) 2.30
Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double-blind randomised trial. BJOG (2010) 2.16
Sequence analysis of the cloned streptococcal cell surface antigen I/II. FEBS Lett (1989) 2.11
Immunization of calves against enterotoxigenic colibacillosis by vaccinating dams with purified K99 antigen and whole cell bacterins. Infect Immun (1979) 2.06
Inhibition by desferrioxamine of in-vitro replication of HIV-1. Lancet (1991) 2.05
Adherence of isolates of Neisseria meningitidis from patients and carriers to human buccal epithelial cells. J Infect Dis (1980) 2.05
Defense mechanisms against bovine herpesvirus: relationship of virus-host cell events to susceptibility to antibody-complement cell lysis. Infect Immun (1975) 1.98
Preliminary characterization of an epitope involved in neutralization and cell attachment that is located on the major bovine rotavirus glycoprotein. J Virol (1985) 1.97
Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens. Infect Immun (1982) 1.96
Morbidity of pertussis in adolescents and adults. J Infect Dis (2000) 1.95
A G protein gamma subunit-like domain shared between RGS11 and other RGS proteins specifies binding to Gbeta5 subunits. Proc Natl Acad Sci U S A (1998) 1.94
Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. J Virol (1993) 1.92
Comparative roles of the Arg-Gly-Asp sequence present in the Bordetella pertussis adhesins pertactin and filamentous hemagglutinin. Infect Immun (1992) 1.85
Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis (2011) 1.84
Interactions of monoclonal antibodies and bovine herpesvirus type 1 (BHV-1) glycoproteins: characterization of their biochemical and immunological properties. Virology (1984) 1.81
Proteins Specified by bovine herpesvirus 1 (infectious bovine rhinotracheitis virus). J Virol (1981) 1.80
Host responses to infectious bovine rhinotracheitis virus. III. Isolation and immunologic activities of bovine T lymphocytes. J Immunol (1974) 1.79
Bordetella parapertussis invasion of HeLa 229 cells and human respiratory epithelial cells in primary culture. Infect Immun (1989) 1.78
Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol Cell Biol (2000) 1.78
Serological response to filamentous hemagglutinin and lymphocytosis-promoting toxin of Bordetella pertussis. Infect Immun (1983) 1.77
Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry (1992) 1.76
Adolescents undergoing surgery for idiopathic scoliosis: how physical and psychological characteristics relate to patient satisfaction with the cosmetic result. Spine (Phila Pa 1976) (2001) 1.75
Host defense mechanisms against infectious bovine rhinotracheitis virus: in vitro stimulation of sensitized lymphocytes by virus antigen. Infect Immun (1974) 1.69
Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med (1998) 1.65
Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine (1997) 1.63
Sarcomatoid variant of anaplastic large-cell Ki-1 lymphoma. Am J Surg Pathol (1990) 1.60
Protection of newborn calves against fatal multisystemic infectious bovine rhinotracheitis by feeding colostrum from vaccinated cows. Can J Vet Res (1987) 1.59
Antibody-dependent cell-mediated cytotoxicity in cows: comparison of effector cell activity against heterologous erthrocyte and herpesvirus-infected bovine target cells. Infect Immun (1976) 1.59
A subunit gIV vaccine, produced by transfected mammalian cells in culture, induces mucosal immunity against bovine herpesvirus-1 in cattle. Vaccine (1994) 1.58
Molecular cloning, sequencing, and expression of functional bovine herpesvirus 1 glycoprotein gIV in transfected bovine cells. J Virol (1990) 1.57
Hemagglutination and hemagglutination-inhibition studies with a strain of Nebraska calf diarrhea virus (bovine rotavirus). Intervirology (1978) 1.57
A clinally varying promoter polymorphism associated with adaptive variation in wing size in Drosophila. Mol Ecol (2010) 1.55
Proline specific peptidases. Biochim Biophys Acta (1997) 1.54
Plasma lipids and lipoproteins and the prevalence of risk for coronary heart disease in Canadian adults. Canadian Heart Health Surveys Research Group. CMAJ (1992) 1.54
Bovine herpesvirus-1 vaccination against experimental bovine herpesvirus-1 and Pasteurella haemolytica respiratory tract infection: onset of protection. Am J Vet Res (1982) 1.54
Role of a cell surface-associated protein in adherence and dental caries. Infect Immun (1991) 1.53
mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response. Mol Cell Biol (1998) 1.53
Comparison of rotavirus strains by hemagglutination inhibition. Can J Microbiol (1978) 1.52
Bovine herpesvirus 1 (BHV-1): biology, pathogenesis, and control. Adv Virus Res (1995) 1.52
Mycotic aneurysms: a case report, clinical review and novel imaging strategy. QJM (2011) 1.51
Synthesis and processing of bovine herpesvirus 1 glycoproteins. J Virol (1986) 1.51
Identification of Bordetella pertussis infection by shared-primer PCR. J Clin Microbiol (1994) 1.49
Incidence of inflammatory myopathies in Victoria, Australia, and evidence of spatial clustering. J Rheumatol (1999) 1.49
Characterization of bovine herpesvirus 1 UL49 homolog gene and product: bovine herpesvirus 1 UL49 homolog is dispensable for virus growth. J Virol (1995) 1.48
Characterization of a murine model of recurrent herpes simplex viral keratitis induced by ultraviolet B radiation. Invest Ophthalmol Vis Sci (1991) 1.47
Indirect airway challenges. Eur Respir J (2003) 1.42
Lipoprotein (a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant (1993) 1.39
Major outbreak of pertussis in northern Alberta, Canada: analysis of discrepant direct fluorescent-antibody and culture results by using polymerase chain reaction methodology. J Clin Microbiol (1993) 1.39
M11L: a novel mitochondria-localized protein of myxoma virus that blocks apoptosis of infected leukocytes. J Exp Med (2000) 1.39
The effect of dose, route and virulence of bovine herpesvirus 1 vaccine on experimental respiratory disease in cattle. Can J Comp Med (1983) 1.39
Bovine herpesvirus 1 attachment to permissive cells is mediated by its major glycoproteins gI, gIII, and gIV. J Virol (1991) 1.38
Should we protect families from patients? Hastings Cent Rep (1998) 1.38
Cloning and in vitro expression of the gene for the E3 haemagglutinin glycoprotein of bovine coronavirus. J Gen Virol (1989) 1.37
Disruption of M-T5, a novel myxoma virus gene member of poxvirus host range superfamily, results in dramatic attenuation of myxomatosis in infected European rabbits. J Virol (1996) 1.37
Phenotypic variation and modulation in Bordetella bronchiseptica. Infect Immun (1984) 1.36
Protection of cattle from bovine herpesvirus type I (BHV-1) infection by immunization with individual viral glycoproteins. Virology (1987) 1.36
Monoclonal antibodies to bovine coronavirus: characteristics and topographical mapping of neutralizing epitopes on the E2 and E3 glycoproteins. Virology (1987) 1.35
Antigenic and immunogenic characteristics of bovine herpesvirus type-1 glycoproteins GVP 3/9 and GVP 6/11a/16, purified by immunoadsorbent chromatography. Virology (1985) 1.35
Host defense mechanisms against infectious bovine rhinotracheitis virus. II. Inhibition of viral plaque formation by immune peripheral blood lymphocytes. Cell Immunol (1975) 1.35
Mechanisms of resistant of herpesviruses: comparison of the effectiveness of different cell types in mediating antibody-dependent cell-mediated cytotoxicity. Infect Immun (1977) 1.34
Mechanisms of recovery from Herpesvirus infections -a review. Can J Comp Med (1978) 1.34
Activation of myosin-I by members of the Ste20p protein kinase family. J Biol Chem (1996) 1.33
Further analysis of the role of calcium in rotavirus morphogenesis. Virology (1987) 1.32
Functional and topographical analyses of epitopes on bovine herpesvirus type 1 glycoprotein IV. Arch Virol (1988) 1.30
Effect of adenosine deaminase upon the antiviral activity in vitro of adenine arabinoside for vaccinia virus. Antimicrob Agents Chemother (1974) 1.30
Genetic heterogeneity within individual bovine rotavirus isolates. J Virol (1982) 1.29
Immune interferon production by lymphoid cells: role in the inhibition of herpesviruses. Infect Immun (1976) 1.29
Plasma lipids and lipoprotein reference values, and the prevalence of dyslipoproteinemia in Canadian adults. Canadian Heart Health Surveys Research Group. Can J Cardiol (1999) 1.28
Fine needle aspiration cytology of breast masses: an evaluation of its accuracy and reasons for diagnostic failure. Ann R Coll Surg Engl (1987) 1.28
Antibacterial activities of extracts from Nigerian chewing sticks. Phytother Res (1999) 1.28
Determination of plaque inhibitory activity of adenine arabinoside (9-beta-D-arabinofuranosyladenine) for herpesviruses using an adenosine deaminase inhibitor. Antimicrob Agents Chemother (1974) 1.28
Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor. Mol Cell Biol (2000) 1.28
The role of antibody dependent cytotoxicity in recovery from herpesvirus infections. Cell Immunol (1976) 1.27
Expression of the myxoma virus tumor necrosis factor receptor homologue and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes. Virology (1996) 1.27
Analysis of bovine herpes virus-type 1 isolates by restriction endonuclease fingerprinting. Arch Virol (1983) 1.26
Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci (1995) 1.25
The interaction between bovine herpesvirus type 1 and activated bovine T lymphocytes. J Gen Virol (1990) 1.25
The direct antiviral cytotoxicity by bovine lymphocytes is not restricted by genetic incompatibility of lymphocytes and target cells. J Immunol (1977) 1.24
Parental willingness to enter a child in a controlled vaccine trial. Clin Invest Med (1998) 1.24
Reactivation of temperature-sensitive and non-temperature-sensitive infectious bovine rhinotracheitis vaccine virus with dexamethasone. Infect Immun (1980) 1.23
Impact of different blood lipid evaluation and treatment guidelines on the proportion of Canadians identified and treated for elevated blood cholesterol. Canadian Heart Health Surveys Research Group. Can J Cardiol (1999) 1.23
Effect of tunicamycin on rotavirus assembly and infectivity. J Virol (1982) 1.23
Topographical analysis of bovine herpesvirus type-1 glycoproteins: use of monoclonal antibodies to identify and characterize functional epitopes. Virology (1985) 1.22
Studies on rotaviral antibody in bovine serum and lacteal secretions, using radioimmunoassay. J Am Vet Med Assoc (1978) 1.22
Comparison of the antiviral effects of 5-methoxymethyl-deoxyuridine with 5-iododeoxyuridine, cytosine arabinoside, and adenine arabinoside. Antimicrob Agents Chemother (1975) 1.21
Characterization of cell-binding properties of bovine herpesvirus 1 glycoproteins B, C, and D: identification of a dual cell-binding function of gB. J Virol (1995) 1.21
Restriction fragment length polymorphisms and sequence variation within the spaP gene of Streptococcus mutans serotype c isolates. Infect Immun (1991) 1.19
Role of the C terminus in antigen P1 surface localization in Streptococcus mutans and two related cocci. J Bacteriol (1996) 1.19
Nuclear localization of the ORF2 protein encoded by porcine circovirus type 2. Virology (2001) 1.19